Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irofulven in Advanced Pancreatic Adenocarcinoma
NCT00003760Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Nov 1998
- Primary completion
- May 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irofulven in pancreatic adenocarcinoma (PDAC), sponsored by UT Health San Antonio. Started Nov 1998; status: completed.
02
Drugs
irofulven
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00003760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003760.